Share Email Print

Proceedings Paper

In vivo tumor characterization using both MR and optical contrast agents with a hybrid MRI-DOT system
Author(s): Yuting Lin; Michael Ghijsen; David Thayer; Orhan Nalcioglu; Gultekin Gulsen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Dynamic contrast enhanced MRI (DCE-MRI) has been proven to be the most sensitive modality in detecting breast lesions. Currently available MR contrast agent, Gd-DTPA, is a low molecular weight extracellular agent and can diffuse freely from the vascular space into interstitial space. Due to this reason, DCE-MRI has low sensitivity in differentiating benign and malignant tumors. Meanwhile, diffuse optical tomography (DOT) can be used to provide enhancement kinetics of an FDA approved optical contrast agent, ICG, which behaves like a large molecular weight optical agent due to its binding to albumin. The enhancement kinetics of ICG may have a potential to distinguish between the malignant and benign tumors and hence improve the specificity. Our group has developed a high speed hybrid MRI-DOT system. The DOT is a fully automated, MR-compatible, multi-frequency and multi-spectral imaging system. Fischer-344 rats bearing subcutaneous R3230 tumor are injected simultaneously with Gd-DTPA (0.1nmol/kg) and IC-Green (2.5mg/kg). The enhancement kinetics of both contrast agents are recorded simultaneously with this hybrid MRI-DOT system and evaluated for different tumors.

Paper Details

Date Published: 10 February 2011
PDF: 6 pages
Proc. SPIE 7892, Multimodal Biomedical Imaging VI, 78920Z (10 February 2011); doi: 10.1117/12.879028
Show Author Affiliations
Yuting Lin, Univ. of California, Irvine (United States)
Michael Ghijsen, Univ. of California, Irvine (United States)
David Thayer, Univ. of California, Irvine (United States)
Orhan Nalcioglu, Univ. of California, Irvine (United States)
Gultekin Gulsen, Univ. of California, Irvine (United States)

Published in SPIE Proceedings Vol. 7892:
Multimodal Biomedical Imaging VI
Fred S. Azar; Xavier Intes, Editor(s)

© SPIE. Terms of Use
Back to Top